New cell sources for CAR-based immunotherapy-Reference-Cited by-同舟云学术

New cell sources for CAR-based immunotherapy

Published:2023-05-06 Issue:1 Volume:11 Page:
ISSN:2050-7771
Container-title:Biomarker Research
language:en
Short-container-title:Biomark Res

Author:

Mazinani Marzieh,Rahbarizadeh Fatemeh

Abstract

AbstractChimeric antigen receptor (CAR) T cell therapy, in which a patient’s own T lymphocytes are engineered to recognize and kill cancer cells, has achieved striking success in some hematological malignancies in preclinical and clinical trials, resulting in six FDA-approved CAR-T products currently available in the market. Despite impressive clinical outcomes, concerns about treatment failure associated with low efficacy or high cytotoxicity of CAR-T cells remain. While the main focus has been on improving CAR-T cells, exploring alternative cellular sources for CAR generation has garnered growing interest. In the current review, we comprehensively evaluated other cell sources rather than conventional T cells for CAR generation.

Publisher

Springer Science and Business Media LLC

Subject

Biochemistry (medical),Clinical Biochemistry,Molecular Medicine

Link

https://link.springer.com/content/pdf/10.1186/s40364-023-00482-9.pdf

Reference257 articles.

1. US Food & Drug Administration. FDA approves axicabtagene ciloleucel for large B-cell lymphoma. 2017. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-axicabtagene-ciloleucel-large-b-cell-lymphoma.

2. US Food & Drug Administration. FDA approves brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma. 2020. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-brexucabtagene-autoleucel-relapsed-or-refractory-mantle-cell-lymphoma.

3. US Food & Drug Administration. FDA approves lisocabtagene maraleucel for second-line treatment of large B-cell lymphoma. 2022.https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lisocabtagene-maraleucel-second-line-treatment-large-b-cell-lymphoma.

4. US Food & Drug Administration. FDA approves idecabtagene vicleucel for multiple myeloma. 2021. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-idecabtagene-vicleucel-multiple-myeloma.

5. US Food & Drug Administration. FDA approves ciltacabtagene autoleucel for relapsed or refractory multiple myeloma. 2022. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ciltacabtagene-autoleucel-relapsed-or-refractory-multiple-myeloma.

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Potential alternatives to αβ-T cells to prevent graft-versus-host disease (GvHD) in allogeneic chimeric antigen receptor (CAR)-based cancer immunotherapy: A comprehensive review;Pathology - Research and Practice;2024-10

2. Beyond CAR-T: The rise of CAR-NK cell therapy in asthma immunotherapy;Journal of Translational Medicine;2024-08-05

3. L’ingénierie cellulaire au service de l’optimisation des CAR-T cells;Bulletin de l'Académie Nationale de Médecine;2024-08

4. Research advances on signaling pathways regulating the polarization of tumor-associated macrophages in lung cancer microenvironment;Frontiers in Immunology;2024-07-31

5. CAR-NKT Cells in Asthma: Use of NKT as a Promising Cell for CAR Therapy;Clinical Reviews in Allergy & Immunology;2024-07-12